Eversept Partners’s Ascendis Pharma A/S ASND Stock Holding History

Eversept Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1M	Buy	+41,621	New	+$9.72M	0.58%	44
2026 Q1	–	Sell	-48,241	Closed	-$10.3M	–	122
2025 Q4	$10.3M	Buy	+48,241	New	+$9.96M	0.52%	51
2022 Q2	–	Sell	-417,172	Closed	-$49M	–	81
2022 Q1	$49M	Buy	417,172 +13,494	+3%	+$1.56M	3.76%	9
2021 Q4	$54.3M	Sell	403,678 -41,525	-9%	-$6.18M	3.47%	8
2021 Q3	$71M	Buy	445,203 +203,429	+84%	+$27.8M	4.91%	2
2021 Q2	$31.8M	Sell	241,774 -70,093	-22%	-$9.34M	2.12%	17
2021 Q1	$40.2M	Buy	311,867 +124,824	+67%	+$19M	2.08%	11
2020 Q4	$31.2M	Buy	187,043 +26,039	+16%	+$4.31M	3.66%	9
2020 Q3	$24.8M	Sell	161,004 -59,340	-27%	-$8.53M	5.52%	4
2020 Q2	$32.6M	Sell	220,344 -55,150	-20%	-$7.57M	4.47%	6
2020 Q1	$31M	Buy	275,494 +72,600	+36%	+$9.43M	7.71%	3
2019 Q4	$28.2M	Sell	202,894 -33,498	-14%	-$3.72M	4.98%	5
2019 Q3	$22.8M	Buy	236,392 +99,995	+73%	+$11.2M	7.06%	5
2019 Q2	$15.7M	Buy	136,397 +33,101	+32%	+$3.96M	4.4%	8
2019 Q1	$12.2M	Buy	103,296 +88,042	+577%	+$7.71M	3.55%	10
2018 Q4	$956K	Sell	15,254 -3,800	-20%	-$239K	0.52%	35
2018 Q3	$1.35M	Sell	19,054 -11,000	-37%	-$757K	0.59%	30
2018 Q2	$2M	Buy	30,054 +6,000	+25%	+$395K	0.91%	27
2018 Q1	$1.57M	Buy	24,054 +11,936	+98%	+$671K	0.73%	28
2017 Q4	$485K	Buy	+12,118	New	+$441K	0.28%	37

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Eversept Partners's ASND Position: Q2 2026 in Review

Eversept Partners opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 41,621 shares worth $11.1M. The stake represents 0.58% of the portfolio and ranks #44 among its holdings. This is a return to the name: Eversept Partners previously reported a position in ASND as recently as Q4 2025.

Eversept Partners first reported a position in ASND in Q4 2017 and has held it in 20 quarters since. The position peaked at $71M in Q3 2021. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Eversept Partners held 41,621 shares of Ascendis Pharma A/S worth $11.1M as of Q2 2026.
Ascendis Pharma A/S was a new Eversept Partners position in Q2 2026.
Ascendis Pharma A/S made up 0.58% of Eversept Partners's portfolio in Q2 2026, its #44 holding.
Eversept Partners first reported a position in Ascendis Pharma A/S in Q4 2017 and has held it in 20 quarters since.
Eversept Partners's Ascendis Pharma A/S position peaked at $71M in Q3 2021.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.